2,013 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Prentiss Smith & Co. Inc.

Prentiss Smith & Co. Inc. purchased a new position in Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,013 shares of the company’s stock, valued at approximately $220,000.

Several other large investors also recently bought and sold shares of RVTY. Parkside Financial Bank & Trust purchased a new position in Revvity during the fourth quarter worth $25,000. Gladius Capital Management LP boosted its stake in Revvity by 84.1% during the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after buying an additional 106 shares during the period. CENTRAL TRUST Co purchased a new position in Revvity during the fourth quarter worth $27,000. ORG Partners LLC purchased a new position in Revvity during the fourth quarter worth $32,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new position in Revvity during the fourth quarter worth $33,000. Institutional investors own 86.65% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Stifel Nicolaus lifted their price objective on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. Raymond James lifted their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Barclays boosted their target price on shares of Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and boosted their target price for the company from $105.00 to $125.00 in a research note on Tuesday, January 16th. Finally, KeyCorp boosted their target price on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.91.

Revvity Stock Down 0.6 %

Shares of RVTY stock traded down $0.59 on Thursday, hitting $102.09. The stock had a trading volume of 461,111 shares, compared to its average volume of 849,016. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average price of $104.72 and a 200 day moving average price of $101.50. The company has a market cap of $12.61 billion, a PE ratio of 18.56, a P/E/G ratio of 2.69 and a beta of 1.09. Revvity, Inc. has a one year low of $79.50 and a one year high of $132.54.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Research analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.27%. Revvity’s payout ratio is currently 5.09%.

Insider Activity at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.